"Fluorouracil" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
| Descriptor ID |
D005472
|
| MeSH Number(s) |
D03.383.742.698.875.404
|
| Concept/Terms |
Fluorouracil- Fluorouracil
- 5FU
- 5-FU
- 5-Fluorouracil
- 5 Fluorouracil
- Fluoruracil
Efudix- Efudix
- Fluoro-Uracile ICN
- Fluoro Uracile ICN
- Efudex
|
Below are MeSH descriptors whose meaning is more general than "Fluorouracil".
Below are MeSH descriptors whose meaning is more specific than "Fluorouracil".
This graph shows the total number of publications written about "Fluorouracil" by people in this website by year, and whether "Fluorouracil" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 3 | 3 |
| 1996 | 1 | 2 | 3 |
| 1997 | 0 | 1 | 1 |
| 1998 | 2 | 4 | 6 |
| 1999 | 1 | 2 | 3 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 2 | 3 |
| 2004 | 2 | 2 | 4 |
| 2005 | 2 | 4 | 6 |
| 2006 | 1 | 2 | 3 |
| 2007 | 2 | 3 | 5 |
| 2008 | 0 | 2 | 2 |
| 2009 | 1 | 6 | 7 |
| 2010 | 1 | 4 | 5 |
| 2011 | 0 | 1 | 1 |
| 2013 | 1 | 1 | 2 |
| 2014 | 1 | 7 | 8 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 3 | 3 |
| 2017 | 0 | 3 | 3 |
| 2018 | 1 | 2 | 3 |
| 2019 | 1 | 2 | 3 |
| 2020 | 1 | 2 | 3 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 2 | 2 |
| 2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fluorouracil" by people in Profiles.
-
Phase II Trial of Induction Chemotherapy for Advanced Sinonasal Squamous Cell Carcinoma. Clin Cancer Res. 2025 Jan 17; 31(2):258-265.
-
MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer. Future Oncol. 2025 Feb; 21(3):303-311.
-
Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline. J Clin Oncol. 2025 Feb 10; 43(5):605-615.
-
The polymeric fluoropyrimidine CF10 overcomes limitations of 5-FU in pancreatic ductal adenocarcinoma cells through increased replication stress. Cancer Biol Ther. 2024 Dec 31; 25(1):2421584.
-
Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer. Clin Cancer Res. 2024 Nov 01; 30(21):4932-4942.
-
Targeted Dynamic Phospho-Proteogenomic Analysis of Gastric Cancer Cells Suggests Host Immunity Provides Survival Benefit. Mol Cell Proteomics. 2024 Dec; 23(12):100870.
-
Phase 1 Trial of Total Neoadjuvant Therapy With Short-Course Chemoradiotherapy Followed by Chemotherapy for Patients With Potentially Resectable Gastric Cancer. Int J Radiat Oncol Biol Phys. 2025 Feb 01; 121(2):423-431.
-
From mitochondria to tumor suppression: ACAT1's crucial role in gastric cancer. Front Immunol. 2024; 15:1449525.
-
Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trials. ESMO Open. 2024 Aug; 9(8):103663.
-
Transarterial (chemo)embolisation versus systemic chemotherapy for colorectal cancer liver metastases. Cochrane Database Syst Rev. 2024 08 09; 8:CD012757.